Get started
Author

Hiroaki Takaya

Observed names: H. Takaya, HIROAKI TAKAYA
ORCID: 0000-0002-4990-7573
Observed ORCID: 0000-0002-4990-7573
OpenAlex ID: A5053207239
The Effect of Inflammatory Cytokines in Alcoholic Liver Disease
2013 · Hideto Kawaratani, Tatsuhiro Tsujimoto, et al. · Mediators of Inflammation · 261
PDF
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
2017 · Kosuke Kaji, Hiroaki Takaya, et al. · World Journal of Gastroenterology · 105
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis
2020 · Masanori Furukawa, Kei Moriya, et al. · Hepatology Research · 86
PDF
Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolization with inhibition of the LPS/TLR4 signaling pathway
2020 · Koji Ishida, Kosuke Kaji, et al. · The Journal of Nutritional Biochemistry · 85
PDF
Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review)
2017 · Hideto Kawaratani, Kei Moriya, et al. · International Journal of Molecular Medicine · 67
PDF
Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis
2021 · Norihisa Nishimura, Kosuke Kaji, et al. · International Journal of Molecular Sciences · 57
PDF
ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child‐Turcotte‐Pugh score and the Model for End‐Stage Liver Disease score
2012 · Hiroaki Takaya, Masahito Uemura, et al. · Hepatology Research · 52
PDF
von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C
2018 · Hiroaki Takaya, Hideto Kawaratani, et al. · United European Gastroenterology Journal · 48
PDF
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
2020 · Kosuke Kaji, Soichiro Saikawa, et al. · Antibiotics · 46
PDF
Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease
2019 · Kazuki Tahara, Takemi Akahane, et al. · JGH Open · 44
PDF
Management of refractory cirrhotic ascites: challenges and solutions
2018 · Hiroshi Fukui, Hideto Kawaratani, et al. · Hepatic Medicine Evidence and Research · 40
PDF
Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
2020 · Yukihisa Fujinaga, Hideto Kawaratani, et al. · International Journal of Molecular Sciences · 39
PDF
VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
2019 · Hiroaki Takaya, Tadashi Namisaki, et al. · BMC Gastroenterology · 37
PDF
Combining probiotics and an angiotensin‐II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non‐alcoholic steatohepatitis
2018 · Yasuhiko Sawada, Hideto Kawaratani, et al. · Hepatology Research · 35
PDF
Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
2015 · Tadashi Namisaki, Ryuichi Noguchi, et al. · Journal of Gastroenterology · 35
Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure
2017 · Hiroaki Takaya, Hitoshi Yoshiji, et al. · Biomedical Reports · 34
PDF
Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor
2021 · Masanori Furukawa, Akira Mitoro, et al. · Clinical Endoscopy · 33
PDF
Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
2020 · Yuki Tsuji, Tadashi Namisaki, et al. · Experimental and Therapeutic Medicine · 33
PDF
Predictive parameter of tolvaptan effectiveness in cirrhotic ascites
2016 · Hideto Kawaratani, Hiroshi Fukui, et al. · Hepatology Research · 31
Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity
2021 · Yuki Fujimoto, Kosuke Kaji, et al. · World Journal of Gastroenterology · 30
Combined treatment with dipeptidyl peptidase‐4 inhibitor (sitagliptin) and angiotensin‐II type 1 receptor blocker (losartan) suppresses progression in a non‐diabetic rat model of steatohepatitis
2016 · Yasushi Okura, Tadashi Namisaki, et al. · Hepatology Research · 30
PDF
The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
2021 · Hirotetsu Takagi, Kosuke Kaji, et al. · Cells · 29
PDF
Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
2020 · Takahiro Ozutsumi, Tadashi Namisaki, et al. · International Journal of Molecular Sciences · 29
PDF
Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model
2018 · Kenichiro Seki, Mitsuteru Kitade, et al. · Oncotarget · 28
PDF
TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats
2019 · Daisuke Kaya, Kosuke Kaji, et al. · Cells · 26
PDF
Works count: 139
Citation count: 2,138
H-index: 25
I10-index: 64
Year
Topic
Type